EU gives go-ahead for Teva-Ivax merger
The Commission concluded that the transaction would not significantly impede effective competition in the European economic area or any substantial part of it. Ivax is a US-based pharmaceutical
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m.